Neuroregeneration in neurodegenerative disorders

BMC Neurology

Volumn 11, Issue , 2011, Pages

  Enciu, Ana M ^a   Nicolescu, Mihnea I ^a,b   Manole, Catalin G ^a,b   Mureşanu, Dafin F ^c   Popescu, Laurenţiu M ^a,b   Popescu, Bogdan O ^a,b  

^a CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b VICTOR BABES NATIONAL INSTITUTE OF PATHOLOGY   (Romania)

^c IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; BROXURIDINE; CYTOKINE; DOUBLECORTIN; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GROWTH FACTOR; NERVE CELL ADHESION MOLECULE; NERVE GROWTH FACTOR; NERVE PROTEIN; NEUROTROPHIN; NEUROTROPHIN 3; NEUROTROPHIN 4; OXIDOPAMINE; RECOMBINANT GROWTH FACTOR; TUC 4 PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; APOPTOSIS; ARTICLE; BRAIN; BRAIN DEPTH STIMULATION; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL (TOPIC); DEGENERATIVE DISEASE; DENTATE GYRUS; DISEASE SEVERITY; DRUG DELIVERY SYSTEM; DYSKINESIA; FIBROBLAST; GENE EXPRESSION; GENE OVEREXPRESSION; HIPPOCAMPUS; HUMAN; IN VITRO STUDY; NERVE CELL; NERVE CELL DIFFERENTIATION; NERVE CELL PLASTICITY; NERVE REGENERATION; NERVOUS SYSTEM DEVELOPMENT; NEURAL STEM CELL; NEURAL STEM CELL TRANSPLANTATION; NEUROIMAGING; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; SIGNAL TRANSDUCTION; SUBVENTRICULAR ZONE; SYNAPSE; TRANSGENIC ANIMAL; ANIMAL; CYTOLOGY; REVIEW;

ALZHEIMER DISEASE; ANIMALS; BRAIN; HUMANS; NERVE REGENERATION; NEURAL STEM CELLS; NEUROGENESIS; PARKINSON DISEASE;

EID: 79959448007     PISSN: None     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/1471-2377-11-75     Document Type: Article

References (104)

1. Johansson BB. Regeneration and plasticity in the brain and spinal cord. J Cereb Blood Flow Metab 2007, 27:1417-1430. 10.1038/sj.jcbfm.9600486, 17392690.
2. Ramon y Cajal S. The Croonian lecture: La fine structure des centres nerveux. Proc Roy Soc London 1894, 55:444-467.
3. Altman J. Autoradiographic study of degenerative and regenerative proliferation of neuroglia cells with tritiated thymidine. Exp Neurol 1962, 5:302-318. 10.1016/0014-4886(62)90040-7, 13860749.
4. Altman J. Are new neurons formed in the brains of adult mammals?. Science 1962, 135:1127-1128. 10.1126/science.135.3509.1127, 13860748.
5. Altman J, Das GD. Autoradiographic and histological evidence of postnatal hippocampal neurogenesis in rats. J Comp Neurol 1965, 124:319-335. 10.1002/cne.901240303, 5861717.
6. McKay R. Stem cells in the central nervous system. Science 1997, 276:66-71. 10.1126/science.276.5309.66, 9082987.
7. Morshead CM, Reynolds BA, Craig CG, McBurney MW, Staines WA, Morassutti D, Weiss S, van der Kooy D. Neural stem cells in the adult mammalian forebrain: a relatively quiescent subpopulation of subependymal cells. Neuron 1994, 13:1071-1082. 10.1016/0896-6273(94)90046-9, 7946346.
8. Reynolds BA, Weiss S. Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system. Science 1992, 255:1707-1710. 10.1126/science.1553558, 1553558.
9. Shihabuddin LS, Palmer TD, Gage FH. The search for neural progenitor cells: prospects for the therapy of neurodegenerative disease. Mol Med Today 1999, 5:474-480. 10.1016/S1357-4310(99)01596-8, 10529788.
10. Lee E, Son H. Adult hippocampal neurogenesis and related neurotrophic factors. BMB Rep 2009, 42:239-244.
11. Chuang TT. Neurogenesis in mouse models of Alzheimer's disease. Biochim Biophys Acta 2010,
12. Haughey NJ, Nath A, Chan SL, Borchard AC, Rao MS, Mattson MP. Disruption of neurogenesis by amyloid beta-peptide, and perturbed neural progenitor cell homeostasis, in models of Alzheimer's disease. J Neurochem 2002, 83:1509-1524. 10.1046/j.1471-4159.2002.01267.x, 12472904.
13. Kolecki R, Lafauci G, Rubenstein R, Mazur-Kolecka B, Kaczmarski W, Frackowiak J. The effect of amyloidosis-beta and ageing on proliferation of neuronal progenitor cells in APP-transgenic mouse hippocampus and in culture. Acta Neuropathol 2008, 116:419-424. 10.1007/s00401-008-0380-4, 18483741.
14. Calafiore M, Battaglia G, Zappala A, Trovato-Salinaro E, Caraci F, Caruso M, Vancheri C, Sortino MA, Nicoletti F, Copani A. Progenitor cells from the adult mouse brain acquire a neuronal phenotype in response to beta-amyloid. Neurobiol Aging 2006, 27:606-613. 10.1016/j.neurobiolaging.2005.03.019, 15964102.
15. Chen Y, Dong C. Abeta40 promotes neuronal cell fate in neural progenitor cells. Cell Death Differ 2009, 16:386-394. 10.1038/cdd.2008.94, 18566600.
16. Sotthibundhu A, Li QX, Thangnipon W, Coulson EJ. Abeta(1-42) stimulates adult SVZ neurogenesis through the p75 neurotrophin receptor. Neurobiol Aging 2009, 30:1975-1985. 10.1016/j.neurobiolaging.2008.02.004, 18374455.
17. Jin K, Peel AL, Mao XO, Xie L, Cottrell BA, Henshall DC, Greenberg DA. Increased hippocampal neurogenesis in Alzheimer's disease. Proc Natl Acad Sci USA 2004, 101:343-347. 314187, 14660786.
18. Li B, Yamamori H, Tatebayashi Y, Shafit-Zagardo B, Tanimukai H, Chen S, Iqbal K, Grundke-Iqbal I. Failure of neuronal maturation in Alzheimer disease dentate gyrus. J Neuropathol Exp Neurol 2008, 67:78-84. 10.1097/nen.0b013e318160c5db, 18091557.
19. Boekhoorn K, Joels M, Lucassen PJ. Increased proliferation reflects glial and vascular-associated changes, but not neurogenesis in the presenile Alzheimer hippocampus. Neurobiol Dis 2006, 24:1-14. 10.1016/j.nbd.2006.04.017, 16814555.
20. Verwer RW, Sluiter AA, Balesar RA, Baayen JC, Noske DP, Dirven CM, Wouda J, van Dam AM, Lucassen PJ, Swaab DF. Mature astrocytes in the adult human neocortex express the early neuronal marker doublecortin. Brain 2007, 130:3321-3335. 10.1093/brain/awm264, 18055496.
21. Ziabreva I, Perry E, Perry R, Minger SL, Ekonomou A, Przyborski S, Ballard C. Altered neurogenesis in Alzheimer's disease. J Psychosom Res 2006, 61:311-316. 10.1016/j.jpsychores.2006.07.017, 16938507.
22. Lovell MA, Geiger H, Van Zant GE, Lynn BC, Markesbery WR. Isolation of neural precursor cells from Alzheimer's disease and aged control postmortem brain. Neurobiol Aging 2006, 27:909-917. 10.1016/j.neurobiolaging.2005.05.004, 15979211.
23. Mazur-Kolecka B, Golabek A, Nowicki K, Flory M, Frackowiak J. Amyloid-beta impairs development of neuronal progenitor cells by oxidative mechanisms. Neurobiol Aging 2006, 27:1181-1192. 10.1016/j.neurobiolaging.2005.07.006, 16105709.
24. Waldau B, Shetty AK. Behavior of neural stem cells in the Alzheimer brain. Cell Mol Life Sci 2008, 65:2372-2384. 10.1007/s00018-008-8053-y, 18500448.
25. Lie DC, Dziewczapolski G, Willhoite AR, Kaspar BK, Shults CW, Gage FH. The adult substantia nigra contains progenitor cells with neurogenic potential. J Neurosci 2002, 22:6639-6649.
26. Liu BF, Gao EJ, Zeng XZ, Ji M, Cai Q, Lu Q, Yang H, Xu QY. Proliferation of neural precursors in the subventricular zone after chemical lesions of the nigrostriatal pathway in rat brain. Brain Res 2006, 1106:30-39. 10.1016/j.brainres.2006.05.111, 16843444.
27. Aponso PM, Faull RL, Connor B. Increased progenitor cell proliferation and astrogenesis in the partial progressive 6-hydroxydopamine model of Parkinson's disease. Neuroscience 2008, 151:1142-1153. 10.1016/j.neuroscience.2007.11.036, 18201835.
28. Nuber S, Petrasch-Parwez E, Winner B, Winkler J, von Horsten S, Schmidt T, Boy J, Kuhn M, Nguyen HP, Teismann P, Schulz JB, Neumann M, Pichler BJ, Reischl G, Holzmann C, Schmitt I, Bornemann A, Kuhn W, Zimmermann F, Servadio A, Riess O. Neurodegeneration and motor dysfunction in a conditional model of Parkinson's disease. J Neurosci 2008, 28:2471-2484. 10.1523/JNEUROSCI.3040-07.2008, 18322092.
29. Hoglinger GU, Rizk P, Muriel MP, Duyckaerts C, Oertel WH, Caille I, Hirsch EC. Dopamine depletion impairs precursor cell proliferation in Parkinson disease. Nat Neurosci 2004, 7:726-735. 10.1038/nn1265, 15195095.
30. Borta A, Hoglinger GU. Dopamine and adult neurogenesis. J Neurochem 2007, 100:587-595. 10.1111/j.1471-4159.2006.04241.x, 17101030.
31. Auld DS, Mennicken F, Quirion R. Nerve growth factor rapidly induces prolonged acetylcholine release from cultured basal forebrain neurons: differentiation between neuromodulatory and neurotrophic influences. J Neurosci 2001, 21:3375-3382.
32. Baquet ZC, Bickford PC, Jones KR. Brain-derived neurotrophic factor is required for the establishment of the proper number of dopaminergic neurons in the substantia nigra pars compacta. J Neurosci 2005, 25:6251-6259. 10.1523/JNEUROSCI.4601-04.2005, 15987955.
33. Klein R. Role of neurotrophins in mouse neuronal development. FASEB J 1994, 8:738-744.
34. Davies AM, Minichiello L, Klein R. Developmental changes in NT3 signalling via TrkA and TrkB in embryonic neurons. EMBO J 1995, 14:4482-4489. 394540, 7556091.
35. Conover JC, Yancopoulos GD. Neurotrophin regulation of the developing nervous system: analyses of knockout mice. Rev Neurosci 1997, 8:13-27. 10.1515/REVNEURO.1997.8.1.13, 9402642.
36. Cohen-Cory S, Kidane AH, Shirkey NJ, Marshak S. Brain-derived neurotrophic factor and the development of structural neuronal connectivity. Dev Neurobiol 70:271-288.
37. Mattson MP. Neuroprotective signaling and the aging brain: take away my food and let me run. Brain Res 2000, 886:47-53. 10.1016/S0006-8993(00)02790-6, 11119686.
38. Cole GM, Frautschy SA. The role of insulin and neurotrophic factor signaling in brain aging and Alzheimer's Disease. Exp Gerontol 2007, 42:10-21. 10.1016/j.exger.2006.08.009, 17049785.
39. Peterson AL, Nutt JG. Treatment of Parkinson's disease with trophic factors. Neurotherapeutics 2008, 5:270-280. 10.1016/j.nurt.2008.02.003, 18394569.
40. Lanni C, Stanga S, Racchi M, Govoni S. The expanding universe of neurotrophic factors: therapeutic potential in aging and age-associated disorders. Curr Pharm Des 16:698-717.
41. Reichardt LF. Neurotrophin-regulated signalling pathways. Philos Trans R Soc Lond B Biol Sci 2006, 361:1545-1564. 10.1098/rstb.2006.1894, 1664664, 16939974.
42. Volosin M, Song W, Almeida RD, Kaplan DR, Hempstead BL, Friedman WJ. Interaction of survival and death signaling in basal forebrain neurons: roles of neurotrophins and proneurotrophins. J Neurosci 2006, 26:7756-7766. 10.1523/JNEUROSCI.1560-06.2006, 16855103.
43. Piltonen M, Bespalov MM, Ervasti D, Matilainen T, Sidorova YA, Rauvala H, Saarma M, Mannisto PT. Heparin-binding determinants of GDNF reduce its tissue distribution but are beneficial for the protection of nigral dopaminergic neurons. Exp Neurol 2009, 219:499-506. 10.1016/j.expneurol.2009.07.002, 19615368.
44. Oo TF, Kholodilov N, Burke RE. Regulation of natural cell death in dopaminergic neurons of the substantia nigra by striatal glial cell line-derived neurotrophic factor in vivo. J Neurosci 2003, 23:5141-5148.
45. Bilang-Bleuel A, Revah F, Colin P, Locquet I, Robert JJ, Mallet J, Horellou P. Intrastriatal injection of an adenoviral vector expressing glial-cell-line-derived neurotrophic factor prevents dopaminergic neuron degeneration and behavioral impairment in a rat model of Parkinson disease. Proc Natl Acad Sci USA 1997, 94:8818-8823. 10.1073/pnas.94.16.8818, 23145, 9238061.
46. Eslamboli A, Georgievska B, Ridley RM, Baker HF, Muzyczka N, Burger C, Mandel RJ, Annett L, Kirik D. Continuous low-level glial cell line-derived neurotrophic factor delivery using recombinant adeno-associated viral vectors provides neuroprotection and induces behavioral recovery in a primate model of Parkinson's disease. J Neurosci 2005, 25:769-777. 10.1523/JNEUROSCI.4421-04.2005, 15673656.
47. Sariola H, Saarma M. Novel functions and signalling pathways for GDNF. J Cell Sci 2003, 116:3855-3862. 10.1242/jcs.00786, 12953054.
48. Jain S, Golden JP, Wozniak D, Pehek E, Johnson EM, Milbrandt J. RET is dispensable for maintenance of midbrain dopaminergic neurons in adult mice. J Neurosci 2006, 26:11230-11238. 10.1523/JNEUROSCI.1876-06.2006, 17065462.
49. Kramer ER, Aron L, Ramakers GM, Seitz S, Zhuang X, Beyer K, Smidt MP, Klein R. Absence of Ret signaling in mice causes progressive and late degeneration of the nigrostriatal system. PLoS Biol 2007, 5:e39. 10.1371/journal.pbio.0050039, 1808500, 17298183.
50. Voutilainen MH, Back S, Porsti E, Toppinen L, Lindgren L, Lindholm P, Peranen J, Saarma M, Tuominen RK. Mesencephalic astrocyte-derived neurotrophic factor is neurorestorative in rat model of Parkinson's disease. J Neurosci 2009, 29:9651-9659. 10.1523/JNEUROSCI.0833-09.2009, 19641128.
51. Lindholm P, Voutilainen MH, Lauren J, Peranen J, Leppanen VM, Andressoo JO, Lindahl M, Janhunen S, Kalkkinen N, Timmusk T, Tuominen RK, Saarma M. Novel neurotrophic factor CDNF protects and rescues midbrain dopamine neurons in vivo. Nature 2007, 448:73-77. 10.1038/nature05957, 17611540.
52. Mattson MP. Glutamate and neurotrophic factors in neuronal plasticity and disease. Ann N Y Acad Sci 2008, 1144:97-112. 10.1196/annals.1418.005, 2614307, 19076369.
53. Tapia-Arancibia L, Aliaga E, Silhol M, Arancibia S. New insights into brain BDNF function in normal aging and Alzheimer disease. Brain Res Rev 2008, 59:201-220. 10.1016/j.brainresrev.2008.07.007, 18708092.
54. Laske C, Stransky E, Leyhe T, Eschweiler GW, Wittorf A, Richartz E, Bartels M, Buchkremer G, Schott K. Stage-dependent BDNF serum concentrations in Alzheimer's disease. J Neural Transm 2006, 113:1217-1224. 10.1007/s00702-005-0397-y, 16362629.
55. Schindowski K, Belarbi K, Buee L. Neurotrophic factors in Alzheimer's disease: role of axonal transport. Genes Brain Behav 2008, 7(Suppl 1):43-56. 2228393, 18184369.
56. Tong L, Balazs R, Thornton PL, Cotman CW. Beta-amyloid peptide at sublethal concentrations downregulates brain-derived neurotrophic factor functions in cultured cortical neurons. J Neurosci 2004, 24:6799-6809. 10.1523/JNEUROSCI.5463-03.2004, 15282285.
57. Hefti F. Development of effective therapy for Alzheimer's disease based on neurotrophic factors. Neurobiol Aging 1994, 15(Suppl 2):S193-194.
58. Mufson EJ, Ikonomovic MD, Styren SD, Counts SE, Wuu J, Leurgans S, Bennett DA, Cochran EJ, DeKosky ST. Preservation of brain nerve growth factor in mild cognitive impairment and Alzheimer disease. Arch Neurol 2003, 60:1143-1148. 10.1001/archneur.60.8.1143, 12925373.
59. O'Bryant SE, Hobson V, Hall JR, Waring SC, Chan W, Massman P, Lacritz L, Cullum CM, Diaz-Arrastia R. Brain-derived neurotrophic factor levels in Alzheimer's disease. J Alzheimers Dis 2009, 17:337-341. 2787708, 19363274.
60. Counts SE, Nadeem M, Wuu J, Ginsberg SD, Saragovi HU, Mufson EJ. Reduction of cortical TrkA but not p75(NTR) protein in early-stage Alzheimer's disease. Ann Neurol 2004, 56:520-531. 10.1002/ana.20233, 15455399.
61. Cuello AC, Bruno MA. The failure in NGF maturation and its increased degradation as the probable cause for the vulnerability of cholinergic neurons in Alzheimer's disease. Neurochem Res 2007, 32:1041-1045. 10.1007/s11064-006-9270-0, 17404842.
62. Cuello AC, Bruno MA, Allard S, Leon W, Iulita MF. Cholinergic involvement in Alzheimer's disease. A link with NGF maturation and degradation. J Mol Neurosci 2010, 40:230-235. 10.1007/s12031-009-9238-z, 19680822.
63. Schulte-Herbruggen O, Hamker U, Meske V, Danker-Hopfe H, Ohm TG, Hellweg R. Beta/A4-Amyloid increases nerve growth factor production in rat primary hippocampal astrocyte cultures. Int J Dev Neurosci 2007, 25:387-390. 10.1016/j.ijdevneu.2007.05.010, 17646078.
64. Chauhan NB, Siegel GJ, Lee JM. Depletion of glial cell line-derived neurotrophic factor in substantia nigra neurons of Parkinson's disease brain. J Chem Neuroanat 2001, 21:277-288. 10.1016/S0891-0618(01)00115-6, 11429269.
65. Eberling JL, Kells AP, Pivirotto P, Beyer J, Bringas J, Federoff HJ, Forsayeth J, Bankiewicz KS. Functional effects of AAV2-GDNF on the dopaminergic nigrostriatal pathway in parkinsonian rhesus monkeys. Hum Gene Ther 2009, 20:511-518. 10.1089/hum.2008.201, 2725183,2725183, 19254173.
66. Ericson C, Georgievska B, Lundberg C. Ex vivo gene delivery of GDNF using primary astrocytes transduced with a lentiviral vector provides neuroprotection in a rat model of Parkinson's disease. Eur J Neurosci 2005, 22:2755-2764. 10.1111/j.1460-9568.2005.04503.x, 16324109.
67. Sun M, Kong L, Wang X, Lu XG, Gao Q, Geller AI. Comparison of the capability of GDNF, BDNF, or both, to protect nigrostriatal neurons in a rat model of Parkinson's disease. Brain Res 2005, 1052:119-129. 10.1016/j.brainres.2005.05.072, 2581863, 16018990.
68. Cao H, Zhang GR, Wang X, Kong L, Geller AI. Enhanced nigrostriatal neuron-specific, long-term expression by using neural-specific promoters in combination with targeted gene transfer by modified helper virus-free HSV-1 vector particles. BMC Neurosci 2008, 9:37. 10.1186/1471-2202-9-37, 2330056, 18402684.
69. Straten G, Eschweiler GW, Maetzler W, Laske C, Leyhe T. Glial cell-line derived neurotrophic factor (GDNF) concentrations in cerebrospinal fluid and serum of patients with early Alzheimer's disease and normal controls. J Alzheimers Dis 2009, 18:331-337.
70. Marksteiner J, Kemmler G, Weiss EM, Knaus G, Ullrich C, Mechteriakov S, Oberbauer H, Auffinger S, Hinterholzl J, Hinterhuber H, Humpel C. Five out of 16 plasma signaling proteins are enhanced in plasma of patients with mild cognitive impairment and Alzheimer's disease. Neurobiol Aging 2009,
71. Nutt JG, Burchiel KJ, Comella CL, Jankovic J, Lang AE, Laws ER, Lozano AM, Penn RD, Simpson RK, Stacy M, Wooten GF. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology 2003, 60:69-73.
72. Thickbroom GW, Mastaglia FL. Plasticity in neurological disorders and challenges for noninvasive brain stimulation (NBS). J Neuroeng Rehabil 2009, 6:4. 10.1186/1743-0003-6-4, 2649147, 19222843.
73. Arendt T. Synaptic degeneration in Alzheimer's disease. Acta Neuropathol 2009, 118:167-179. 10.1007/s00401-009-0536-x, 19390859.
74. Walsh DM, Selkoe DJ. Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron 2004, 44:181-193. 10.1016/j.neuron.2004.09.010, 15450169.
75. Rowan MJ, Klyubin I, Cullen WK, Anwyl R. Synaptic plasticity in animal models of early Alzheimer's disease. Philos Trans R Soc Lond B Biol Sci 2003, 358:821-828. 1693153, 12740129.
76. Lacor PN, Buniel MC, Furlow PW, Clemente AS, Velasco PT, Wood M, Viola KL, Klein WL. Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J Neurosci 2007, 27:796-807. 10.1523/JNEUROSCI.3501-06.2007, 17251419.
77. Gong Y, Chang L, Viola KL, Lacor PN, Lambert MP, Finch CE, Krafft GA, Klein WL. Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci USA 2003, 100:10417-10422. 10.1073/pnas.1834302100, 193576, 12925731.
78. Arendt T, Bruckner MK. Linking cell-cycle dysfunction in Alzheimer's disease to a failure of synaptic plasticity. Biochim Biophys Acta 2007, 1772:413-421.
79. Mikkonen M, Soininen H, Tapiola T, Alafuzoff I, Miettinen R. Hippocampal plasticity in Alzheimer's disease: changes in highly polysialylated NCAM immunoreactivity in the hippocampal formation. Eur J Neurosci 1999, 11:1754-1764. 10.1046/j.1460-9568.1999.00593.x, 10215928.
80. Jorgensen OS, Brooksbank BW, Balazs R. Neuronal plasticity and astrocytic reaction in Down syndrome and Alzheimer disease. J Neurol Sci 1990, 98:63-79. 10.1016/0022-510X(90)90182-M, 1977892.
81. Min SS, Quan HY, Ma J, Han JS, Jeon BH, Seol GH. Chronic brain inflammation impairs two forms of long-term potentiation in the rat hippocampal CA1 area. Neurosci Lett 2009, 456:20-24. 10.1016/j.neulet.2009.03.079, 19429126.
82. Arendt T, Stieler J, Strijkstra AM, Hut RA, Rudiger J, Van der Zee EA, Harkany T, Holzer M, Hartig W. Reversible paired helical filament-like phosphorylation of tau is an adaptive process associated with neuronal plasticity in hibernating animals. J Neurosci 2003, 23:6972-6981.
83. Watson JB, Hatami A, David H, Masliah E, Roberts K, Evans CE, Levine MS. Alterations in corticostriatal synaptic plasticity in mice overexpressing human alpha-synuclein. Neuroscience 2009, 159:501-513. 10.1016/j.neuroscience.2009.01.021, 2670358, 19361478.
84. Steidl JV, Gomez-Isla T, Mariash A, Ashe KH, Boland LM. Altered short-term hippocampal synaptic plasticity in mutant alpha-synuclein transgenic mice. Neuroreport 2003, 14:219-223. 10.1097/00001756-200302100-00012, 12598733.
85. Picconi B, Ghiglieri V, Bagetta V, Barone I, Sgobio C, Calabresi P. Striatal synaptic changes in experimental parkinsonism: role of NMDA receptor trafficking in PSD. Parkinsonism Relat Disord 2008, 14(Suppl 2):S145-149.
86. Deutch AY, Colbran RJ, Winder DJ. Striatal plasticity and medium spiny neuron dendritic remodeling in parkinsonism. Parkinsonism Relat Disord 2007, 13(Suppl 3):S251-258.
87. Mufson EJ, Kordower JH. Cortical neurons express nerve growth factor receptors in advanced age and Alzheimer disease. Proc Natl Acad Sci USA 1992, 89:569-573. 10.1073/pnas.89.2.569, 48280, 1309947.
88. Chen KS, Gage FH. Somatic gene transfer of NGF to the aged brain: behavioral and morphological amelioration. J Neurosci 1995, 15:2819-2825.
89. Frim DM, Uhler TA, Galpern WR, Beal MF, Breakefield XO, Isacson O. Implanted fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevent 1-methyl-4-phenylpyridinium toxicity to dopaminergic neurons in the rat. Proc Natl Acad Sci USA 1994, 91:5104-5108. 10.1073/pnas.91.11.5104, 43940, 8197193.
90. Smith DE, Roberts J, Gage FH, Tuszynski MH. Age-associated neuronal atrophy occurs in the primate brain and is reversible by growth factor gene therapy. Proc Natl Acad Sci USA 1999, 96:10893-10898. 10.1073/pnas.96.19.10893, 17979, 10485922.
91. Tuszynski MH, Thal L, Pay M, Salmon DP, U HS, Bakay R, Patel P, Blesch A, Vahlsing HL, Ho G, Tong G, Potkin SG, Fallon J, Hansen L, Mufson EJ, Kordower JH, Gall C, Conner J. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med 2005, 11:551-555. 10.1038/nm1239, 15852017.
92. Bradford HF. The use of foetal human brain tissue as brain implants: phenotype manipulation by genetic manipulation and biochemical induction. Keio J Med 2002, 51:148-153.
93. Defer GL, Geny C, Ricolfi F, Fenelon G, Monfort JC, Remy P, Villafane G, Jeny R, Samson Y, Keravel Y, Gaston A, Degos JD, Peschanski M, Cesaro P, Nguyen JP. Long-term outcome of unilaterally transplanted parkinsonian patients. I. Clinical approach. Brain 1996, 119(Pt 1):41-50.
94. Hauser RA, Freeman TB, Snow BJ, Nauert M, Gauger L, Kordower JH, Olanow CW. Long-term evaluation of bilateral fetal nigral transplantation in Parkinson disease. Arch Neurol 1999, 56:179-187. 10.1001/archneur.56.2.179, 10025423.
95. Mendez I, Sanchez-Pernaute R, Cooper O, Vinuela A, Ferrari D, Bjorklund L, Dagher A, Isacson O. Cell type analysis of functional fetal dopamine cell suspension transplants in the striatum and substantia nigra of patients with Parkinson's disease. Brain 2005, 128:1498-1510. 10.1093/brain/awh510, 2610438, 15872020.
96. Mendez I, Vinuela A, Astradsson A, Mukhida K, Hallett P, Robertson H, Tierney T, Holness R, Dagher A, Trojanowski JQ, Isacson O. Dopamine neurons implanted into people with Parkinson's disease survive without pathology for 14 years. Nat Med 2008, 14:507-509. 10.1038/nm1752, 2656682, 18391961.
97. Freed CR, Greene PE, Breeze RE, Tsai WY, DuMouchel W, Kao R, Dillon S, Winfield H, Culver S, Trojanowski JQ, Eidelberg D, Fahn S. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 2001, 344:710-719. 10.1056/NEJM200103083441002, 11236774.
98. Geraerts M, Krylyshkina O, Debyser Z, Baekelandt V. Concise review: therapeutic strategies for Parkinson disease based on the modulation of adult neurogenesis. Stem Cells 2007, 25:263-270. 10.1634/stemcells.2006-0364, 17082225.
99. Barzilay R, Levy YS, Melamed E, Offen D. Adult stem cells for neuronal repair. Isr Med Assoc J 2006, 8:61-66.
100. Bjorklund LM, Sanchez-Pernaute R, Chung S, Andersson T, Chen IY, McNaught KS, Brownell AL, Jenkins BG, Wahlestedt C, Kim KS, Isacson O. Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model. Proc Natl Acad Sci USA 2002, 99:2344-2349. 10.1073/pnas.022438099, 122367, 11782534.
101. Wang Q, Matsumoto Y, Shindo T, Miyake K, Shindo A, Kawanishi M, Kawai N, Tamiya T, Nagao S. Neural stem cells transplantation in cortex in a mouse model of Alzheimer's disease. J Med Invest 2006, 53:61-69. 10.2152/jmi.53.61, 16537997.
102. Sadan O, Shemesh N, Cohen Y, Melamed E, Offen D. Adult neurotrophic factor-secreting stem cells: a potential novel therapy for neurodegenerative diseases. Isr Med Assoc J 2009, 11:201-204.
103. Apel C, Forlenza OV, de Paula VJ, Talib LL, Denecke B, Eduardo CP, Gattaz WF. The neuroprotective effect of dental pulp cells in models of Alzheimer's and Parkinson's disease. J Neural Transm 2009, 116:71-78. 10.1007/s00702-008-0135-3, 18972063.
104. Murrell W, Wetzig A, Donnellan M, Feron F, Burne T, Meedeniya A, Kesby J, Bianco J, Perry C, Silburn P, Mackay-Sim A. Olfactory mucosa is a potential source for autologous stem cell therapy for Parkinson's disease. Stem Cells 2008, 26:2183-2192. 10.1634/stemcells.2008-0074, 18535154.